Human serum preβ1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases by Yunqin Chen et al.
RESEARCH Open Access
Human serum preβ1-high density
lipoprotein levels are independently and
negatively associated with coronary artery
diseases
Yunqin Chen1,2†, Jibin Dong3†, Xueying Chen1†, Hui Jiang1, Ahmed Bakillah2, Xiaojin Zhang4, Zhiqiang Li1, Jia Yin5,
Donghui Liang5, Yunzeng Zou1, Mahmood Hussain2, Marina Cuchel6, Daniel Rader5, Haozhu Chen1, Junbo Ge1*
and Xian-Cheng Jiang2*
Abstract
Background: Serum preβ1-high density lipoprotein (preβ1-HDL) was defined by two-dimensional non-denaturing
linear gel electrophoresis and apolipoprotein A-I immuno-blotting. Serum preβ1-HDL seems to play an important
role in reverse cholesterol transport, a well-known anti-atherosclerosis process. However, there are still debatable
questions for its quantification and coronary artery disease (CAD) relevance.
Methods: We isolated the preβ1-HDL using a new native polyacrylamide gel electrophoresis (PAGE) system and
lipid pre-staining serum. We established a two-demensional gel electrophoresis system.
Results: We measured the preβ1-HDL in Tangier disease patients and subjects with cholesterol ester transfer
protein (CETP) mutation. The preβ1-HDL is clearly separated from lipid-free apoA-I monomer and cannot be
converted into other HDL particles under lecithin-cholesterol acyltransferase (LCAT) inhibition. This preβ1-HDL
is a spheroidal particle with the highest apoA-1/cholesterol ratio and highest density (≥1.21 g/ml), as compared with
all other HDLs. Importantly, we found that serum from subjects with Tangier disease or with cholesterol ester transfer
protein (CETP) mutation have no detectible preβ1-HDL particles. We recruited a total of 102 subjects underwent
diagnostic coronary angiography and measured their preβ1-HDL levels. Among them, 56 had no stenosis of
coronary artery and 46 were diagnosed as CAD, which was predefined as the presence of a luminal diameter
stenosis ≥50 % in at least 1 major coronary artery territory. We found that preβ1-HDL is independently and
negatively associated with the severity of the coronary artery stenosis (Gensini score).
Conclusion: We established a novel and simple method for human serum preβ1-HDL quantification. We found
that human lower preβ1-HDL is an independent predictor for severer coronary artery stenosis.
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Background
HDL cholesterol concentration in the blood is inversely
proportional to coronary artery disease (CAD) risk [1].
This relationship is thought to be mediated by the ability
of HDL to transport excess cholesterol from peripheral
tissues back to the liver for excretion, a process known as
reverse cholesterol transport [2]. An understanding of the
molecular events in HDL formation is thus prerequisite
for the development of therapeutic strategies to raise
HDL cholesterol levels and protect against atheroscler-
osis. However, recent research has indicated that HDL
particles are very heterogeneous, and indeed increasing
total HDL cholesterol does not reduce CAD risk [3–8].
Thus, it is important to characterize each HDL particle
subclass in terms of its pro- or anti-atherogenicity.
There are many subclasses of HDL depending on the
analytical technique used for separation. HDL can be sep-
arated from non-HDL by chemical precipitation methods
[9–11]. Likewise, HDL can be separated into HDL2 and
HDL3 by ultracentrifugation [12, 13]. HDL particle size
distribution can also be assessed by native PAGE [14, 15].
Two-dimensional nondenaturing linear gel electrophor-
esis, immunoblotting, and image analysis were first
utilized by Castro and Fielding in 1988 to describe preβ1-
HDL, preβ2-HDL, and αHDL [16]. Although free apoA-I
was not seen on the two-dimensional gel in that first
paper [16], Francone et al. from the same lab clearly
showed that lipid-free apoA-I could be separated from
preβ1-HDL [17]. In 1993, Asztalos et al. used a modified
two-dimensional gel system to define 12 subfractions of
HDL, including preβ1-HDL and preβ2-HDL, but they did
not indicate whether the preβ1-HDL they identified con-
tained lipid-free apoA-I or not [18]. Since then, the same
method has been utilized in many clinical studies, includ-
ing those concerning CAD patients, and the results sug-
gest that an elevated level of preβ1-HDL is a risk factor
for CAD [19–21]. The same method was used to show
that subjects with Tangier disease still have preβ1-HDL
but that HDL maturation is impaired [22]. Miyazaki et al.
very recently showed that in their hand the so-called
“preβ1-HDL” is, in fact, lipid-free monomolecular apoA-I
[23]. Thus, it is necessary to re-valuate how preβ1-HDL is
defined and measured. In this study, we established a dir-
ect measurement for preβ1-HDL in human serum. More-
over, we found no detectible preβ1-HDL in Tangier
patients and in the subjects with cholesterol ester transfer
protein (CETP) mutation. Importantly, preβ1-HDL is re-
duced in CAD patients.
Methods
A new native polyacrylamide gel electrophoresis (PAGE)
system
We used the following six solutions (also see Fig. 1a). 1)
Solution A: Acrylamide (9.60 g; Fluca) and 0.25 g N,N’-
methylenebisacrylamide (Fluca) in deionized water to
100 ml final volume. 2) Solution B: Tris (18.30 g) to
24 ml of 1 N HCl and diluted to 100 ml final volume
with deionized water. 3) Solution C: Acrylamide
(19.60 g) and 0.40 g N,N’-methylenebisacrylamide in
deionized water to 100 ml final volume. 4) Solution
D: Tris (6.06 g) and 1.17 g EDTA-Na2 in deionized
water to 100 ml final volume. 5) Staining solution:
Sudan Black-B (0.125 g; Sigma) to 25 ml isopropano-
l:ethylene glycol (4:1, V/V), mixed well, and incubated
in a water bath at 37 °C overnight. 6) Running buffer:
Tris (6.0 g) and 28.8 g glycine in deionized water to
1000 ml final volume, and then diluted 10-fold with
deionized water before use.
The gradient gels in 6 × 100 mm glass tubes were pre-
pared as indicated in Fig. 1a. Each tube gel comprised
three layers differing in polyacrylamide concentration
(7.0, 3.6, and 3.0 %) and height (45 mm, 40 mm, and
7 mm, respectively). Each gel tube was inserted vertically
into an electrophoretic cell (DYY-III 27B Model, Liuyi
Inc., Beijing). The upper and lower chambers of the elec-
trophoretic cell contained ~400 ml and ~600 ml running
buffer, respectively. Serum (100 μl) was mixed with 10 μl
of staining solution, and 50 μl was loaded on the top of
the tube gel; electrophoresis was carried out for 2.5 h at
100 V. After electrophoresis, each tube was subjected to
densitometry (604 nm; Model CS-9301, Shimadzu, Inc.
Japan). The sum of the peak areas was taken as the total
amount of blood lipids, and the percentage of each lipo-
protein fraction was calculated automatically by the
densitometer.
A new two- dimensional gel electrophoresis system
Serum (4 μl) was applied to a 0.75 % agarose gel (2 mm
thick) and subjected to electrophoresis with a Sub-Cell®
GT Cell apparatus (Bio-Rad) in a buffer containing
25 mM Tris (pH 8.6) at 100 V for 1.5 h. Gel strips were
then excised and placed on top of nonlinear gradient slab
gels. Slab gels were prepared as shown in Fig. 2a and had
the same gradient setting as tube gels (Fig. 1a). The
second-dimension electrophoresis was carried out in an
XCell SureLock™ Mini-Cell apparatus (Life Technologies)
in a buffer containing 5 mM Tris and 38.4 mM glycine
(pH 8.4) at 100 V for 3 h. The separated proteins were
transferred to a nitrocellulose membrane. Immunoblotting
for apoA-I was performed using polyclonal anti-human
apoA-I (Abcam). Horseradish peroxidase–conjugated
rabbit polyclonal anti-goat lgG (Novus Biologicals) was
used as a secondary antibody. The SuperSignal Westen
detection Kit (Pierce) was used for detection.
Ultracentrifugation
Human serum (6 ml) was adjusted to 1.30 g/ml by add-
ing 2.93 g of KBr. The sample was then added into a
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28 ml ultracentrifuge (polyallomer) tube and overlaid
with KBr solution (1.063 g/ml) till full. Ultracentrifuga-
tion was performed (Rotor: 50.2Ti) with a Beckman L8-
M at 40,000 rpm at 10 °C for 10 h. Fractions (1 ml of
each) were collected with a long needle from the bottom
to top. The density of each fraction was weighed (800 μl
was weighed on a scale, Explorer, OHAUS). Each frac-
tion was desalted and concentrated through centricon
filters (Millipore) to a final volume of 0.5 ml. These sam-
ples were then used for tube gel and two-dimensional
gel electrophoresis.
Electron microscopy
The HDL subclasses were eluted from gels, dialyzed
against a solution of 0.4 % NH4HCO3, and then proc-
essed as described [24]. An aliquot of lipoprotein solu-
tion was mixed with an equal volume of 2 % sodium
phosphotungstate (pH 7.4). A small droplet was applied
to a Formvar-grid, where it remained for 30 s. The size
and morphology of lipoprotein particles were immedi-
ately observed under a transmission electron microscope
(JEM-1200EX, Japan) operating at 80 KV. Micrographs
were recorded at instrument magnifications of 100 K.
Fig. 1 Native PAGE system to separate HDL subclasses. a Diagram depicting gel preparation in our new system. Electrophoresis proceeded in the
downward direction. Solutions A–D are described in Methods. TEMED, N,N,N’,N’-tetramethylethylenediamine; APS, ammonium persulfate. b Tube-gel
PAGE of human serum. HDL (V) was indicated in red. CV, interassay coefficient of variation; QC, quality control. c Samples were from: a normal neonate,
a normal adult, a patient with acute myocardial infarction (AMI), and an adult carrying a CETP mutation. HDL (V) was indicated in red. d Representative
densitometric scans
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The diameter of 100 scattered particles in each lipopro-
tein fraction was measured using the software of Image-
Pro Plus 6.0 (Media Cybernetics, Inc. USA).
Human study population
The study complied with the Declaration of Helsinki,
and was approved by the hospital ethical review board
(Zhongshan Hospital, Fudan University, Shanghai,
China). A total of 102 subjects underwent diagnostic
coronary angiography in Zhongshan Hospital, Fudan
University were included in this study, among which, 56
had no stenosis of coronary artery and 46 were diag-
nosed as CAD, which was predefined as the presence of
a luminal diameter stenosis ≥50 % in at least 1 major
coronary artery territory (left anterior descending, left
circumflex or right coronary artery or their major
branches). The severity of the coronary artery stenosis
was evaluated by Gensini score [25], which is computed
by assigning a severity score to each coronary stenosis
according to the degree of luminal narrowing and its
geographic importance. Reductions in the lumen
diameter of 25 %, 50 %, 75 %, 90 %, 99 % and
complete occlusion were given score of 1, 2, 4, 8, 16
and 32, respectively. Each principal vascular segment
was assigned a multiplier in accordance with the
functional significance of the myocardial area supplied
by that segment, that is, the LM was assigned the sig-
nificant multiplier × 5; the proximal segment of the
LAD × 2.5; the proximal segment of the LCX × 2.5;
the mid segment of the LAD × 1.5; the RCA, the dis-
tal segment of the LAD, the posterolateral artery, and
the obtuse marginal artery × 1; and others × 0.5. Dia-
betes mellitus (DM) was diagnosed by clinical history,
use of hypoglycemic medications or a fasting blood
sugar level >7.0 mmol/L (125 mg/dL); hypertension
was defined in patients receiving antihypertensive
treatment or with known diagnosis of hypertension
(blood pressure ≥140/90 mmHg).
Fig. 2 Distribution of apoA-I in human serum determined by nondenaturing two-dimensional nonlinear gradient gel electrophoresis. a Schematic
diagram of the gel system. b Human serum (4 μl) from each of a neonate and adult was subjected to electrophoresis on a 0.75 % agarose gel
(first dimension) for 1 h. The lane was then excised and placed on a nonlinear gradient polyacrylamide slab gel (second dimension) and subjected
to electrophoresis for 3 h. Serum proteins were transferred to a nitrocellulose membrane, and human apoA-I was visualized with goat anti-human
apoA-I. The red arrowhead indicates the distance of particle migration in the electrophoresis. c Diagram showing HDL subspecies (in adults)
isolated by two-dimensional gel electrophoresis
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Statistical analysis
Continuous variables were reported as means ± stand-
ard deviation (SD). Comparisons among more than
two groups were performed by analysis of variance
(ANOVA), followed by least significant difference
(LSD) test for multiple comparisons. The Pearson’s χ2
test was used to assess statistical differences in di-
chotomous and categorical variables. Univariate linear
regression analysis was used to determine correlation
between Gensini score and HDL-(V) (preβ1-HDL)
levels. Attempts were also made to predict CAD by
multivariate logistic regression analysis, using CAD as
the dependent variable, and age, gender, BMI, smok-
ing history, hypertension, DM, HDL-(V) (preβ1-HDL),
HDL-(A), HDL-(B), and HDL-(C) levels as independ-
ent variables. To further investigate the relationships
between Gensini score and clinical characteristics or
laboratory parameters, multivariate linear regression
analysis was performed by using Gensini score as the
dependent variable, and age, gender, BMI, smoking
history, hypertension, DM, HDL-(A), HDL-(B), HDL-
(C), and HDL-(V) (preβ1-HDL) levels as independent
variables. P values < 0.05 were considered statistically
significant. All analyses were done using SPSS version
16 analytical software (SPSS Inc., Chicago, IL).
Biochemical detection
Blood lipids were determined according to standard pro-
cedures [26] in the clinical laboratory of Zhongshan
Hospital. Lipid concentrations were measured on a
Hitachi 911 automatic analyzer, using reagents from
Roche Diagnostics. Cholesterol and triglyceride con-
centrations were determined enzymatically using
CHOD-PAP and lipase/GPO/PAP methods, respect-
ively. HDL-cholesterol (HDL-C) concentration was
measured with the phosphotungstic acid and MgCl2
precipitation approach. LDL-cholesterol (LDL-C) was
measured by a direct method, not calculated. The
levels of apoAI, apoB, apoE, and Lipoprotein (a) [Lp (a)]
were determined by immunoturbidimetric assays.
Other human samples
Three CETP mutant (with G→A in the splice donor
site of intron 14 [27]) serums were a gift from Dr.
Akihiro Inazu, Department of Clinical Laboratory Sci-
ence, Kanazawa.
Six Tangier disease serums were from Division of
Translational Medicine and Human Genetics, Perelman
School of Medicine, University of Pennsylvania.
Results
The makeup of the native polyacrylamide gels that we
developed is shown in Fig. 1a. Non-gradient polyacryl-
amide gels of 3.0, 3.6, and 7.0 % acrylamide were used
for VLDL, LDL, and HDL separation, respectively.
Moreover, this system could separate HDL (HDL total)
into four fractions denoted here as HDL-(A), (B), (C),
and (V) (Fig. 1b). The precision of the assays was estab-
lished by carrying out ten assays for each of the HDL
subclasses in a pooled human adult serum sample. The
interassay coefficient of variation for each HDL subclass
is shown in Fig. 1b.
We next sought to determine the distribution of these
HDL subclasses in different human serum samples. We
found that neonates had significantly higher HDL (A)
than healthy adults and HDL (B) was the predominant
HDL particle in healthy adults. Subjects carrying a CETP
mutation had much higher HDL (A) levels than all the
tested samples (Fig. 1c, d). Importantly, we found that
our system could quantitatively separate HDL-(V) from
the other subclasses. The order of its abundance was as
follows: neonates > healthy adults > persons with a CETP
mutation.
To characterize these HDL subclasses, we created a
new system for two-dimensional gel electrophoresis. All
serum lipoproteins were first separated by agarose gel
electrophoresis (Fig. 2a). The gel strips were then excised
and placed on top of a nonlinear gradient slab gel. As
shown in Fig. 2b, this new system yielded patterns com-
parable with those reported by Francone et al. [17]. We
also noticed that human adults had much higher α-HDL
and preβ2-HDL compared with neonates, whereas neo-
nates had not only higher preβ1-HDL but also more
preβ1-HDL subspecies (Fig. 2b, c).
To further characterize HDL particles, we isolated
them by ultracentrifugation (Fig. 3a) and then subjected
the Sudan Black pre-stained particles (with different
densities) to electrophoresis on our native PAGE gel.
We found that HDL-(V), which was well separated from
the other HDLs, had the highest density (Fig. 3b). Two-
dimensional gel electrophoresis showed that HDL-(V) is,
in fact, preβ1-HDL [17], which had a density about
1.21 g/ml (Fig. 3c).
To further evaluate that HDL-(V) is preβ1-HDL, we
treated human serum with DTNB (1 mM) to inhibit
LCAT [28] and then ran the pre-stained serum on the
native PAGE gel. We found that without DTNB treat-
ment, HDL-(V) gradually disappeared during the 6-h in-
cubation, indicating a LCAT-mediated process for HDL
maturation, from preβ1-HDL (nascent HDL) to matured
HDL. However, DTNB treatment could prevent this
process (Fig. 4).
We next determined the particle size of the isolated
HDL subclasses using electron microscopy with a
negative-staining approach. A scattered pattern of isolated
HDL particles was observed at 100,000× magnification
(Fig. 5a). All particles were spheroidal. The preβ1-HDLs
were visualized as small dot-like particles rather than disc-
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like ones in which they exhibited a weak contrast. The
mean diameter of the HDL particles was as follows: (A) =
11 nm, (B) = 9 nm, (C) = 7 nm, and preβ1-HDL = 5 nm.
We also measured apoA-I and cholesterol levels in each
fraction and found that preβ1-HDL had the highest
apoA-I/cholesterol ratio, indicating that although it is
lipid poor it is not lipid free (Fig. 5b). This was con-
sistent with the results obtained from our native
PAGE because the lipids in each HDL were pre-
stained with Sudan Black (Fig. 1b, c).
We analyzed Tangier patient pre-stained serum
(pooled from 5 samples) on our native PAGE gel and
found that there was no preβ1-HDL (Fig. 6a). However,
when we ran the same sample on our two-dimensional
gel, we found there was a preβ1-HDL-like spot (Fig. 6b),
suggesting that the two-dimensional gel cannot distin-
guish real preβ1-HDL particles and preβ1-HDL-like
apoA-I aggregates. To see the lipid-free apoA-I aggre-
gate does exist, we ran purified apoA-I (Sigma) on the
two-dimensional gel and found the apoA-I sample
contains preβ1-HDL-like/lipid-free apoA-I aggregates
(Fig. 6c). Thus, the two-dimensional gel system cannot
precisely quantify preβ1-HDL in human serum.
Further, we utilized our one-dimensional method to
measure preβ1-HDL levels in 102 human subjects.
Concerning that Gensini sore > 60 was related to severe
coronary artery stenosis and poor prognosis [25], all
these 102 subjects were divided into three groups accord-
ing to Gensini score (group 1, Gensini score = 0, n = 56;
group 2, Gensini score 0 ~ 60, n = 22; group 3, Gensini
score > 60, n = 24). Clinical characteristics and parameters
of the three groups and significant differences are shown
in Table 1. Smoking history, levels of HDL-C, preβ1-HDL,
HDL-(A), HDL-(B), and IDL were significantly different in
the three groups. Further multiple comparisons by LSD
test showed significant difference between every two
groups in smoking history, levels of preβ1-HDL, and IDL
(Table 1, Fig. 7a).
By multivariate logistic regression analysis (Table 2),
both smoking history and preβ1-HDL (aOR = 0.13, p =
0.05) levels in CAD patients were found to be independ-
ently associated with CAD.
Fig. 3 HDL (V) is preβ1-HDL. To prove that HDL-(V) is preβ1-HDL, we isolated different HDL fractions by ultracentrifugation. a Isolation of
non-HDL and HDL particles using ultracentrifugation. b Each fraction was subjected to our new PAGE system. The red arrowhead indicates
HDL (V). c Each fraction was subjected to our new two-dimensional gel electrophoresis and then immunoblotted with anti-apoA-I. HDL-(V) exhibited
an electrophoretic pattern identical to that preβ1-HDL
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To study the relationship between the severity of cor-
onary artery stenosis and preβ1-HDL levels, univariate
linear regression analysis was performed to show a nega-
tive correlation between Gensini score and preβ1-HDL
levels (r = −0.394, p < 0.0001, Fig. 7b). Further, using multi-
variate linear regression analysis, DM (B = 43.57, p = 0.01)
and preβ1-HDL levels (B = −37.33, p = 0.01) were in-
dependently associated with Gensini score after ad-
justed for age, gender, BMI, hypertension, HDL-(A),
HDL-(B), and HDL-(C) levels (Table 3). Thus, preβ1-
HDL levels are independent predictors of higher
Gensini score.
Discussion
In this study, we 1) developed a new native PAGE sys-
tem which quantitatively separates a smaller HDL parti-
cles from other HDL particles; 2) demonstrated that this
HDL fraction is preβ1-HDL, which can be converted to
other HDLs by LCAT; 3) found that preβ1-HDL parti-
cles thus isolated are spheroidal with the highest apoA-
I/cholesterol ratio and highest density (≥1.21 g/ml),
compared with all other HDL particles; 4) found that ne-
onates have significantly higher and more complex preβ-
HDLs than adults; 5) found that Tangier patients and
CETP mutation have no detectable preβ-HDLs; 6) found
Fig. 5 Characterization of HDL subclasses. a Size and shape of particles of the HDL subclasses as viewed with electron microscopy. The mean
diameter of the particles of preβ1-HDL (red arrows), HDL-(C), HDL-(B), and HDL-(A) was 5 nm, 7 nm, 9 nm, and 11 nm, respectively. The
bar indicates 100 nm. b ApoA-I/cholesterol ratios in 9 separated samples
Fig. 4 LCAT inhibition blocks preβ1-HDL conversion. Human serum was treated with or without DTNB (1.8 mM) and then pre-stained with Sudan
Black. The sample was run on the gel
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that the existing two-dimensional gel system cannot pre-
cisely quantify preβ1-HDL in human serum; and 7)
found that preβ1-HDL is significantly related to the se-
verity of coronary artery stenosis in a negative manner.
One of the key accomplishments of this study is that we
established a simple and fast method for preβ1-HDL
quantification. It has been reported that HDL subclasses
can be defined by either of two gradient PAGE systems
[14, 15], but the resolution of neither system is ideal. The
novelty of our system is that we assemble three different
polyacrylamide gels (3.0, 3.6, and 7.0 % acrylamide) to sep-
arate VLDL, LDL, and HDL and also to separate HDL
subclasses in a single-step electrophoresis. The biggest dif-
ference between our native PAGE system and previous
systems is that we can clearly resolve HDL (V), i.e. preβ1-
HDL (Fig. 1b), whereas other systems cannot detect this
fraction [14, 15]. Moreover, our system has a small inter-
assay coefficient of variation (Fig. 1b).
The second key accomplishment of this study is that
we established a new system for HDL two-dimensional
gel electrophoresis. It has been reported that HDL
subclasses can be defined on two-dimensional systems
(agarose/linear gradient polyacrylamide gel) [17, 20].
Based on these reported systems, we established our
own agarose/nonlinear gradient PAGE system applicable
to any typical research or clinical laboratory (Fig. 2).
Preβ1-HDL has unique characteristics. We found that
preβ1-HDL particles isolated with our PAGE system have
higher density (≥1.21 g/ml; Fig. 3a, b) than other HDLs,
and this was confirmed by two-dimensional gels (Fig. 3c).
With respect to particle structure, many studies have pos-
tulated that preβ1-HDL is discoidal [29–32], but no report
has shown this directly. Discoidal HDL, having an electro-
phoretic mobility like that of preβ1-HDL, can be synthe-
sized in vitro to serve as a model for plasma preβ-HDL
[31, 33]. Our electron microscopy analysis revealed no dis-
coidal particles but rather only spheroidal particles
(Fig. 5a), similar to a previous report [23]. Moreover, we
also found that preβ1-HDL contains lipids (Figs. 1b, c and
5b), which is different from the previous report [23].
Plasma preβ1-HDL plays an important role in cholesterol
efflux, but it remains controversial whether preβ1-HDL is the
Fig. 6 A two-dimensional gel system cannot precisely quantify preβ1-HDL. a Tangier patient (pooled from 5 subjects) and control serum running
on the native PAGE system as shown in Fig. 1. b Tangier sample running on the two-dimensional gel system. c purified apoA-I (200 ng) running
on the two-dimensional gel system
Chen et al. Nutrition & Metabolism  (2016) 13:36 Page 8 of 12
Table 1 Group comparisons for different variables in different Gensini score groups: Continuous variables are given as means ± SD
and evaluated using analysis of variance (ANOVA), followed by least significant difference (LSD) test for multiple comparisons.
Dichotomous and categorical variables are given as percentages and and compared using Pearson’s χ2 test
Variable Group 1
(Gensini score = 0, n = 56)
Group 2
(Gensini score = 0 ~ 60, n = 22)
Group 3
(Gensini score >60, n = 24)
p value
Male (N%) 43 (76.8 %) 18 (81.8 %) 18 (75.0 %) 0.845
Age (years) 59.75 ± 12.67 57.82 ± 13.83 65.83 ± 9.70 0.062
BMI (kg/m2) 23.85 ± 4.21 25.58 ± 3.18 23.39 ± 3.30 0.122
Smoking (N%) 3 (18.8 %) 15 (68.2 %) 13 (54.2 %) 0.009
0.003 (Group 1 vs. 2)
0.025 (Group 1 vs. 3)
0.331 (Group 2 vs. 3)
Hypertension (N%) 9 (56.2 %) 12 (54.5 %) 14 (58.3 %) 0.967
DM (N%) 2 (12.5 %) 4 (18.2 %) 6 (25.0 %) 0.609
TC (mmol/L) 4.35 ± 0.74 4.20 ± 1.14 4.52 ± 1.10 0.507
TG (mmol/L) 1.29 ± 0.56 1.62 ± 0.93 1.71 ± 1.27 0.077
HDL-C (mmol/L) 1.39 ± 0.31 1.09 ± 0.19 1.14 ± 0.29 <0.0001
<0.0001 (Group 1 vs. 2)
<0.0001 (Group 1 vs. 3)
0.507 (Group 2 vs. 3)
LDL-C (mmol/L) 2.39 ± 0.58 2.38 ± 0.90 2.62 ± 0.84 0.381
ApoAI (mg/mL) 0.97 ± 0.13 0.98 ± 0.15 1.08 ± 0.23 0.078
ApoB (mg/mL) 0.70 ± 0.19 0.82 ± 0.29 0.88 ± 0.30 0.143
ApoE (mg/L) 43.52 ± 12.78 46.05 ± 17.38 51.87 ± 20.65 0.309
Lp (a) (mg/L) 187.40 ± 182.46 191.16 ± 179.62 188.22 ± 191.16 0.998
HDL-(A) (%) 1.94 ± 0.77 1.48 ± 0.64 1.81 ± 0.71 0.048
0.014 (Group 1 vs. 2)
0.451 (Group 1 vs. 3)
0.135 (Group 2 vs. 3)
HDL-(B) (%) 19.11 ± 6.73 13.70 ± 4.77 15.46 ± 6.24 0.001
0.011 (Group 1 vs. 2)
0.018 (Group 1 vs. 3)
0.343 (Group 2 vs. 3)
HDL-(C) (%) 10.45 ± 2.36 11.15 ± 2.97 9.69 ± 2.89 0.171
Preβ1-HDL (%) 1.69 ± 0.34 1.48 ± 0.47 1.24 ± 0.42 <0.0001
0.032 (Group 1 vs. 2)
<0.0001 (Group 1 vs. 3)
0.047 (Group 2 vs. 3)
LDL (%) 41.90 ± 5.88 42.81 ± 7.02 44.34 ± 5.92 0.268
IDL (%) 3.58 ± 1.06 5.14 ± 1.71 6.02 ± 2.28 <0.0001
<0.0001 (Group 1 vs. 2)
<0.0001 (Group 1 vs. 3)
0.006 (Group 2 vs. 3)
VLDL (%) 16.37 ± 6.10 20.12 ± 8.38 17.95 ± 8.24 0.116
BMI body mass index, DM diabetes mellitus, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein
cholesterol, ApoAI apolipoprotein A, ApoB apolipoprotein B, ApoE apolipoprotein E, Lp (a) Lipoprotein (a). The sum of the peak areas (after scanning see Fig. 1) was taken
as the total amount of plasma lipoproteins, and the percentage (%) of each lipoprotein fraction was calculated automatically by the densitometer
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substrate or the first product of ABCA1-mediated cholesterol
efflux [34, 35]. It has been reported that “preβ1-HDL-like”
lipid-poor apoA-1 or nascent HDL is formed when lipid-free
apoA-1 retrieves phospholipids and cholesterol from cells
mediated by ABCA1 in experiments using various culture
cells [36, 37]. Thus, the levels of preβ1-HDL should be an
indicator of the capacity for HDL production and reverse
cholesterol transport, and preβ1-HDL should be expected to
have an anti-atherogenic function. However, the results from
literatures suggest that an elevated level of preβ1-HDL is a
risk factor for CAD [19–21]. This could be due the two-
dimensional electrophoresis cannot separate preβ1-HDL
from the lipid-free apoA-I. Our new two-dimensional gel sys-
tem not only separated preβ1-HDL from the lipid-free apoA-
I, but also demonstrated a complex pattern of preβ1-HDL,
which was not reported before (Fig. 2b, c).
Two-dimensional electrophoresis system is not suit-
able for preβ1-HDL measurement. It has been reported
that patients with Tangier disease have preβ1-HDLs, but
not mature HDL [22]. However, when we carefully re-
checked the two-dimensional electrophoresis gel pre-
sented in current study, the homozygous patient might
only have lipid-free apoA-I (as recently suggested by
Miyazaki et al. [23]). Importantly, we found that samples
from subjects with Tangier disease do not contain
preβ1-HDLs when using our one-dimensional native
PAGE gel (Fig. 6a), however, when we examined the
sample on our two-dimensional gel system, we did find
a preβ1-HDL-like spot (Fig. 6b), probably consisting in
preβ1-HDL-like/lipid-free apoA-I aggregates (Fig. 6c).
Thus, the two-dimensional gel system cannot precisely
quantify preβ1-HDL in human serum. It is reasonable to
Fig. 7 Comparisons of preβ1-HDL levels in patients having different Gensini score. a There were 56, 22 and 24 individuals having Gensini score 0,
0 ~ 60 and >60, respectively. Mean preβ1-HDL levels among the 3 groups were significant different by ANOVA test (p < 0.0001). By LSD test, there
were significant different preβ1-HDL levels between Gensini score 0 and 0 ~ 60 (* p = 0.0032), 0 and >60 († p <0.0001), and 0 ~ 60 and >60 (‡ p =
0.047). b Univariate linear regression analysis showed a negative correlation between Gensini score and preβ1-HDL levels (r = −0.394, p < 0.0001)
Table 2 Logistic regression predictors of CAD: Logistic regression
analysis was performed by using CAD as the dependent variable,
and age, gender, BMI, smoking history, hypertension, DM,
preβ1-HDL, HDL-(A), HDL-(B), and HDL-(C) as independent variables
Variables p value aOR 95.0 % C.I. for aOR
Age (years) 0.31 1.04 (0.96-1.14)
Male gender 0.43 1.93 (0.37-9.99)
BMI (kg/m2) 0.27 1.14 (0.90-1.45)
Smoking 0.03 9.77 (1.28-74.64)
Hypertension 0.97 1.03 (0.17-6.22)
DM 0.95 1.08 (0.10-11.67)
HDL-(A) 0.10 4.75 (0.73-30.86)
HDL-(B) 0.11 0.84 (0.68-1.04)
HDL-(C) 0.52 0.91 (0.68-1.22)
Preβ1-HDL 0.05 0.13 (0.02-1.02)
Table 3 Predictors of Gensini score by multivariate linear
regression: Multivariate linear regression analysis was performed
by using Gensini score as the dependent variable, and age,
gender, BMI, smoking history, hypertension, DM, HDL-(A), HDL-(B),
HDL-(C), and preβ1-HDL levels as independent variables
Variables p value B 95 % confidence interval for B
Age (years) 0.10 1.10 (−0.23-2.43)
Male gender 0.62 8.22 (−24.80-41.24)
BMI (kg/m2) 0.25 −2.39 (−6.46-1.69)
Smoking 0.44 11.74 (−18.77-42.25)
Hypertension 0.58 8.60 (−22.75-39.95)
DM 0.01 43.57 (10.06-77.07)
HDL-(A) 0.31 13.06 (−12.65-38.76)
HDL-(B) 0.32 −1.73 (−5.20-1.74)
HDL-(C) 0.50 −1.86 (−7.09-3.38)
Preβ1-HDL 0.01 −37.33 (−66.61- -8.05)
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infer that Tangier patients have only lipid-free apoA-I
(which could be monomer and polymer or aggregate) but
have no preβ1-HDL, since they have no ABCA1-mediated
cholesterol efflux and preβ1-HDL cannot be formed, thus,
no apoA-I-containing mature HDL can be produced.
Using our new one-dimensional PAGE system, we can
precisely separate preβ1-HDL from the rest of HDL.
This relatively simple method helped us to re-evaluate
the relationship between preβ1-HDL and CAD. We
found that preβ1-HDL levels are independently and
negatively associated with the severity of the coronary
artery stenosis (Table 3, Fig. 7a, b).
Interestingly, we also found that subjects carrying a
CETP mutation have not only larger HDLs but also no de-
tectible preβ1-HDL with our system (Fig. 1c). This preβ1-
HDL deficiency may be one of the reasons why CETP in-
hibitors, to date, do not work in the expected direction,
i.e., to reduce the incidence of cardiovascular diseases.
Another interesting observation from this study is that
neonates have much higher and more complex preβ1-
HDLs than adults, indicating that there are age-related
changes in the characteristics of circulating preβ1-HDLs.
If we can slow down such changes, we may find a new
way to slow down the development of atherosclerosis.
We also observed some interesting phenomena, few
of which have been reported before (Table 1). We
found that 1) in healthy adults, HDL-(B) is the major
HDL particle, and 2) neonates have a dramatically dif-
ferent pattern of HDL subclasses compared with
healthy adults. Although we do not know the physio-
logical relevance of these differences, we now have, at
least, a way to view them.
There are some limitations of our system. The prep-
aration of tube gels is time consuming; however, this
process can be standardized. Further optimization is
needed to improve the resolution of HDL-(A), −(B),
and -(C). Regardless, the simple method for preβ1-HDL
quantification we developed is suitable for clinical ap-
plications and may also be appropriate for screening
potential drugs that may increase the level of circulat-
ing preβ1-HDLs.
Conclusion
We established a novel and simple method for human
serum preβ1-HDL quantification. We found that human
lower preβ1-HDL is an independent predictor for se-
verer coronary artery stenosis.
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